Brought to you by 
Biovail to market Acadia's pimavanserin; terminated
07 Mar 2016
Executive Summary
Acadia Pharmaceuticals (CNS and glaucoma candidates) has granted Biovail's Biovail Laboratories International SRL US and Canadian rights to its Phase III selective 5-HT2A inverse agonist pimavanserin for neurological and psychiatric diseases. Acadia retains rights in all other territories.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biovail to market Acadia's pimavanserin; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice